Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line Ida/Metho/L-asparaginase/Dex chemotherapy in adult blastic plasmacytoid dendritic cell neoplasm
2018-001644-61Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, asparaginase escherichia coli, idarubicin and dexamethasone in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by CHU de Besançon. Primary endpoint: Complete remission or complete remission with incomplete marrow recovery after 3 cycles. Started May 2018; status: completed.
02
Drugs
methotrexateasparaginase escherichia coliidarubicindexamethasone
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on 2018-001644-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001644-61.